ClinicalTrials.Veeva

Find clinical trials for Chronic Lymphocytic Leukemia in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near Seattle, WA, USA:

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...

Enrolling
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

AstraZeneca
AstraZeneca

Seattle, Washington, United States and 42 other locations

This phase II trial is to evaluate the effects of acalabrutinib in combination with venetoclax in treating patients with chronic lymphocytic...

Enrolling
Refractory Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Acalabrutinib

Phase 2

Fred Hutchinson Cancer Center (FHCC)
Fred Hutchinson Cancer Center (FHCC)

Seattle, Washington, United States

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic le...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Seattle, Washington, United States and 11 other locations

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib

Phase 2

Janssen
Janssen

Seattle, Washington, United States and 15 other locations

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

Tacoma, Washington, United States and 130 other locations

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...

Active, not recruiting
Lymphoma, Small Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Biological: JCAR017 (lisocabtagene maraleucel)
Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax

Phase 1, Phase 2

Juno Therapeutics

Seattle, Washington, United States and 66 other locations

study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lympho...

Enrolling
Small Lymphocytic Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia
Drug: Venetoclax
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

Seattle, Washington, United States and 67 other locations

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Tacoma, Washington, United States and 231 other locations

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Seattle, Washington, United States and 196 other locations

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Lymphoma, Non Hodgkin
Drug: BTCT4465A (Mosunetuzumab) IV
Drug: BTCT4465A (Mosunetuzumab) SC

Phase 1, Phase 2

Genentech
Genentech

Seattle, Washington, United States and 48 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems